Clinical significance of CTNNB1 mutation and Wnt pathway activation in endometrioid endometrial carcinoma - Wikidata - wikimedia - TriplyDB

Clinical significance of CTNNB1 mutation and Wnt pathway activation in endometrioid endometrial carcinoma

Clinical significance of CTNNB1 mutation and Wnt pathway activation in endometrioid endometrial carcinoma

http://www.wikidata.org/entity/Q34354361

about

Endometrial Carcinoma: Role of Current and Emerging Biomarkers in Resolving Persistent Clinical Dilemmas SALL4 as an Epithelial-Mesenchymal Transition and Drug Resistance Inducer through the Regulation of c-Myc in Endometrial Cancer Genome-wide analysis of gynecologic cancer: The Cancer Genome Atlas in ovarian and endometrial cancer.Limited impact of intratumour heterogeneity on molecular risk assignment in endometrial cancer.Hsa-microRNA-181a is a regulator of a number of cancer genes and a biomarker for endometrial carcinoma in patients: a bioinformatic and clinical study and the therapeutic implication.Phase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma.Molecular profiling of endometrial carcinoma precursor, primary and metastatic lesions suggests different targets for treatment in obese compared to non-obese patients.miR-137 Targets p160 Steroid Receptor Coactivators SRC1, SRC2, and SRC3 and Inhibits Cell Proliferation.Molecular staging of gynecological cancer: What is the future?Identifying aggressive forms of endometrioid-type endometrial cancer: new insights into molecular subtyping.Novel kinase fusion transcripts found in endometrial cancer Long non-coding RNA profiling links subgroup classification of endometrioid endometrial carcinomas with trithorax and polycomb complex aberrations.Integrative bioinformatic analyses of an oncogenomic profile reveal the biology of endometrial cancer and guide drug discovery.Tumor mutational analysis of GOG248, a phase II study of temsirolimus or temsirolimus and alternating megestrol acetate and tamoxifen for advanced endometrial cancer (EC): An NRG Oncology/Gynecologic Oncology Group study Pancancer modelling predicts the context-specific impact of somatic mutations on transcriptional programs.Epidemiology of Endometrial Carcinoma: Etiologic Importance of Hormonal and Metabolic Influences.Progression inference for somatic mutations in cancer.CTNNB1 (beta-catenin) mutation identifies low grade, early stage endometrial cancer patients at increased risk of recurrence.Beta-catenin and estrogen signaling collaborate to drive cyclin D1 expression in developing mouse prostate.Mutation status coupled with RNA-sequencing data can efficiently identify important non-significantly mutated genes serving as diagnostic biomarkers of endometrial cancer.Lean Body Weight and Metformin Are Insufficient to Prevent Endometrial Hyperplasia in Mice Harboring Inactivating Mutations in PTEN.Hypermethylation of WIF1 and its inhibitory role in the tumor growth of endometrial adenocarcinoma.Exon 3 mutations of CTNNB1 drive tumorigenesis: a review.Precision oncology in the age of integrative genomics.Endometrial Cancers With Activating KRas Mutations Have Activated Estrogen Signaling and Paradoxical Response to MEK Inhibition.Next-Generation Sequencing.Computational development of a molecular-based approach to improve risk stratification of endometrial cancer patients.5-Hydroxy-4'-Nitro-7-Propionyloxy-Genistein Inhibited Invasion and Metastasis via Inactivating Wnt/b-Catenin Signal Pathway in Human Endometrial Carcinoma Ji Endometrial Cells.Predicting high-risk endometrioid carcinomas using proteins.Targeted Therapies in Type II Endometrial Cancers: Too Little, but Not Too Late MiR-452 promotes an aggressive colorectal cancer phenotype by regulating a Wnt/β-catenin positive feedback loop

P2860

Q28074769-A5FDB526-6CDA-485C-AD01-A15779CA0203 Q28548494-2B3ABBDD-59BD-4B7E-AD3A-F1E940F16A41 Q33598001-5C8E8D0A-C5A4-429A-A3BF-51352E205DCA Q33648936-F781A9B1-3A21-41C4-BA61-D7060EA023CD Q35125641-B5448C74-525C-4DFD-9DCD-A10C013A5297 Q35144264-CFA0C296-5FF4-4608-B92A-26DC3D5EA6D5 Q35176084-776CFD75-AAEB-463E-8593-CF87A631E8A9 Q35897588-1AD6D456-B3E3-4997-9D4A-3CA568BE3A9B Q35940829-BE8B36F9-D637-4FEF-8B01-DF26C8F67990 Q36263947-AC7ACB1E-C572-4989-B331-BE6B96CCF565 Q36393068-1DFBF279-91AB-487D-9EF9-3766ACDC7C18 Q36545494-E70FC62B-53E1-45D4-801C-6E6867034E9A Q36905799-DFCDFA6E-D827-4218-8056-27EC35525D8F Q37429034-1B69DCBE-F7CB-4BC2-B249-F873FA8A149E Q37622585-A62E223D-F8E1-4E76-A2AE-13194917E7EE Q38788210-88A3D92D-EAD3-480B-8412-1B7683AF64F5 Q38793244-88CB8873-64B5-4E45-AC5F-E747B188D759 Q40986278-8A447027-8196-4237-A276-419EFA970510 Q46178440-6190D528-1C10-487C-B8AB-D7CAB3D6347F Q47131591-0C851740-09BE-4555-B003-0A4B59CE71DB Q47252413-832B2801-4E26-4AAF-8068-9DAE39A19E6E Q47629102-FC67B759-24A8-462B-9DD8-5756F69D54A4 Q49427525-253FF8B5-6A33-432C-84A0-5740678F0511 Q50105699-F1B2B848-14F1-4A8F-A0E7-8319AAE896D5 Q51006519-E4696049-BA45-466E-B28A-46FD0F394140 Q51032285-311D2318-2362-4337-BFBF-8D9B36E7C509 Q54940052-9EEE1F29-CA11-4F4A-8C7C-0640153D5E3D Q55097522-18D8930E-9691-4DE7-B722-84D9D2DC1DE3 Q55368257-22A1208B-1B59-4122-AB90-36B58FC1918F Q57169683-9146B588-358C-4C7D-86F2-A4E80ED49ACF Q58698448-CA2FC7C8-982C-4406-8208-0437110B5603

P2860

Clinical significance of CTNNB1 mutation and Wnt pathway activation in endometrioid endometrial carcinoma

http://www.wikidata.org/entity/Q34354361

description

2014 nî lūn-bûn

@nan

2014 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Clinical significance of CTNNB ...... metrioid endometrial carcinoma

@ast

Clinical significance of CTNNB ...... metrioid endometrial carcinoma

@en

Clinical significance of CTNNB ...... metrioid endometrial carcinoma

@nl

type

label

Clinical significance of CTNNB ...... metrioid endometrial carcinoma

@ast

Clinical significance of CTNNB ...... metrioid endometrial carcinoma

@en

Clinical significance of CTNNB ...... metrioid endometrial carcinoma

@nl

prefLabel

Clinical significance of CTNNB ...... metrioid endometrial carcinoma

@ast

Clinical significance of CTNNB ...... metrioid endometrial carcinoma

@en

Clinical significance of CTNNB ...... metrioid endometrial carcinoma

@nl

P1433

Q34354361-C606DE96-AE91-4514-87C9-B93714140191

P1476

Q34354361-5FC0367D-69BD-4D1C-89E9-03154BEADAE0

P2093

Q34354361-0C948FAD-5537-4693-AB4C-9B4B2EC698B1

Q34354361-0E56F2BF-6CFB-482A-B92C-86C031F0957F

Q34354361-2A531195-1DDD-44DA-B850-5006A5AEF8C9

Q34354361-34719D95-6FC5-47BA-A50F-C6DFD4582876

Q34354361-397F94E7-90F0-4741-9007-025358CE0D66

Q34354361-7217F463-F97E-4DC2-8279-70077D4F10E3

Q34354361-87A29176-53CC-450B-9851-FC24B91F92FC

Q34354361-B0B08375-34D1-4794-B6DD-471949ED1557

Q34354361-BF1EF406-CCDD-41EE-A3CE-B13D43827822

Q34354361-FCDF51C3-174E-4319-B8C1-F45166A6540F

P2860

Q34354361-02F0B585-AE1A-4A86-BCC8-D8CD4563B7EA

Q34354361-091AF6BA-202F-4E3B-B940-450BBEAFB6C9

Q34354361-13ACF52F-8E55-48B4-91B6-B637A15BC2E4

Q34354361-140AFF1E-8D8A-43CB-95AD-67F2D8E750D4

Q34354361-2359B5B5-17FA-4062-B543-DCD6C33F9C4E

Q34354361-2BC630DC-B32A-4A48-B838-E234217C12E2

Q34354361-3F6A7898-7B8A-46C7-8090-D0277F42C9EC

Q34354361-4129BB91-FB25-440A-BB39-8F588AF614BD

Q34354361-431205D2-54A2-41F0-BE64-AA16835FA52F

Q34354361-4A5D0C6C-072D-4934-8DE0-78F5A210CF89

P31

Q34354361-7C4F08FB-5930-4E0F-AED7-57CBFBE333B5

P356

Q34354361-EB0D676C-FD66-4CDF-A547-14AF43F5245B

P407

Q34354361-65A80877-3E86-477B-A8D6-57682A449479

P433

Q34354361-5DA332F8-567C-4931-A7FA-AD2C00357153

P478

Q34354361-6EF96007-92C3-4371-A513-6965F1C9335C

P50

Q34354361-35B47FB3-BBD2-4B5F-A933-05C7FC7C3117

Q34354361-956CFF2F-82B2-4128-856F-1882052D4275

P577

Q34354361-8800DD7C-9598-4E2C-9BAB-BC857B37B322

P5875

Q34354361-27C75FE2-09F6-4D3A-9660-1854B0DCB8A0

P698

Q34354361-DD677772-E10B-4B6A-B47F-E90C9BF4A30D

P932

Q34354361-B17745F7-A6AC-4BE5-8382-5A8AE1DBDC49

P356

P1433

Journal of the National Cancer Institute

P1476

Clinical significance of CTNNB ...... metrioid endometrial carcinoma

@en

P2093

Anil K Sood

http://www.w3.org/2001/XMLSchema#string

Douglas A Levine

http://www.w3.org/2001/XMLSchema#string

Elaine R Mardis

http://www.w3.org/2001/XMLSchema#string

Gordon B Mills

http://www.w3.org/2001/XMLSchema#string

Karen H Lu

http://www.w3.org/2001/XMLSchema#string

Li Ding

http://www.w3.org/2001/XMLSchema#string

Raju Kucherlapati

http://www.w3.org/2001/XMLSchema#string

Russell R Broaddus

http://www.w3.org/2001/XMLSchema#string

Wei Zhang

http://www.w3.org/2001/XMLSchema#string

Yuexin Liu

http://www.w3.org/2001/XMLSchema#string

P2860

Identification of c-MYC as a target of the APC pathway

Constitutive transcriptional activation by a beta-catenin-Tcf complex in APC-/- colon carcinoma

Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.

Comprehensive molecular characterization of human colon and rectal cancer

Wnt/β-catenin signaling and disease

Cancer statistics, 2013

Control of beta-catenin phosphorylation/degradation by a dual-kinase mechanism

Integrated genomic characterization of endometrial carcinoma

Modulation of morphogenesis by noncanonical Wnt signaling requires ATF/CREB family-mediated transcriptional activation of TGFbeta2

PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes

P31

scholarly article

P356

10.1093/JNCI/DJU245

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

106

http://www.w3.org/2001/XMLSchema#string

P50

Ilya Shmulevich

P577

2014-09-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

265606805

http://www.w3.org/2001/XMLSchema#string

P698

25214561

http://www.w3.org/2001/XMLSchema#string

P932

4200060

http://www.w3.org/2001/XMLSchema#string